
    
      This study is a prospective, open label, phase I/II pilot study. For Treatment Groups A and
      B, the duration of study will include a 5 month enrollment period and approximately 7 months
      of follow-up. For Treatment Group C, the duration of study will include a 3 month enrollment
      period and approximately 7 months of follow-up.
    
  